Frazier Life Sciences XI Buys $10M of ATTO Stock at $17, Converts Preferred Shares
ATTO is trading near its 52-week low of $19.63 (4.7% above the low) on light trading volume (0.2× avg).
Summary
Frazier Life Sciences XI, a 10% owner of Attovia Therapeutics, purchased $10 million of common stock at $17.00 per share and converted preferred shares into 5.49 million common shares upon the IPO closing.
Key Events · Ownership and Investor Activity · ATTO
-
$10M Open-Market Purchase
Frazier Life Sciences XI bought 588,235 shares at $17.00 each, totaling $9,999,995, on August 6, 2026.
-
Preferred Stock Conversion
Four series of preferred stock (A-1, A-2, B, C) automatically converted into 5,490,629 common shares upon the IPO closing, at a 9.29:1 ratio.
-
Post-Transaction Holdings
After the purchase and conversions, Frazier Life Sciences XI directly holds 6,154,213 shares of Attovia common stock.
-
Purchase Near 52-Week Low
The $17.00 purchase price is below the current $20.56 and near the 52-week low of $19.63, suggesting the investor sees value at depressed levels.
Analysis · ATTO · Life Sciences
Frazier Life Sciences XI, a 10% owner, made a $10 million open-market purchase of Attovia Therapeutics common stock at $17.00 per share — a price below the current $20.56 and near the 52-week low. The purchase is accompanied by the automatic conversion of four series of preferred stock into 5.49 million common shares upon the IPO closing, bringing total post-transaction holdings to 6.15 million shares. While the conversion is mechanical, the cash purchase signals conviction from a major institutional investor at a depressed valuation, especially given the stock's proximity to its 52-week low.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATTO was trading at $20.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $785.2M. The 52-week trading range was $19.63 to $22.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.